JLE

Médecine thérapeutique / Pédiatrie

MENU

Anti-HPV vaccination: An overview Volume 21, issue 2, Avril-Mai-Juin 2018

Figures


  • Figure 1

Tables

Authors
Hôpital Universitaire Necker Enfants Malades, Service d’endocrinologie, gynécologie et diabétologie pédiatrique, Centre de référence des pathologies gynécologiques rares, 149, rue de Sèvres, 75743 Paris Cedex 15
* Tirés à part

Cervical cancer is the 11th most common cancer among women. It is mainly due to an infection by a virus from the human Papillomavirus (HPV) family. They cause the most common sexually transmitted infection, and it is estimated that some 80 % of women will experience HPV during their sex life. In France, the prevention of precancerous and cancerous cervical lesions is based on vaccination AND cervical cervix screening for all women aged 25 to 65. This vaccination is recommended for all girls aged 11 to 14 (schema 2 injections) with a possible catch up until age 19 (schema 3 injections). It prevents about 70% of the infections (90% with Gardasil 9®) involved in cervical cancer and significantly reduces pre-cancerous lesions. The most frequently reported adverse events are benign reactions and should not compromise the benefit-risk balance of this vaccination. In France, vaccination coverage is insufficient and all health professionals must commit to achieve the expected preventive efficacy.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License